

5. References

Acampora, D., Merlo, G. R., Paleari, L., Zerega, B., et al. (1999). Craniofacial, vestibular and bone defects in mice lacking the Distal-less-related gene *Dlx5*. *Development* **126**, 3795-3809.

Alliston, T., Choy, L., Ducey, P., Harsenty, G., and Derynck, R. (2001). TGF- β -induced repression of CBFA1 by Smad3 decreases *cbfa1* and osteocalcin expression and inhibits osteoblast differentiation. *Embo J.* **20**, 2254-2272.

Angel, P., Imagawa, M., Chiu, R., Stein, B., Imbra, R. J., Rahmsdorf, H. J., Jonat, C., Herrlich, P., and Karin, M. (1987). Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. *Cell* **49**, 729-739.

Backlund, M. G., Trasti, S. L., Backlund, D. C., Cressman, V. L., Godfrey, V., and Koller, B. H. (2001). Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice. *Cancer Res.* **61**, 6577-6582.

Bakiri, L., Lallemand, D., Bossy-Wetzel, E., and Yaniv, M. (2000). Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclinD1 expression. *Embo J.* **19**, 2056-2068.

Behrens, A., Haigh, J., Mehta-Grigoriou, F., Nagy, A., Yaniv, M., Wagner, E. F. (2003). Impaired intervertebral disc formation in the absence of *Jun*. *Development* **130**, 103-109.

Behrens, A., Jochum, W., Sibilio, M., and Wagner, E. F. (2000). Oncogenic transformation by *ras* and *fos* requires c-Jun N-terminal phosphorylation. *Oncogene* **26**, 2657-2663.

Behrens, A., Sibilina, M., David, J. P., Möhle-Steinlein, U., Tronche, F., Schütz, G., and Wagner E. F. (2002). Impaired hepatocyte proliferation and liver regeneration in mice lacking *c-jun* in the liver. *Embo J.* **21**, 1782-1790.

Behrens, A., Sibilina, M., and Wagner, E. F. (1999). Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. *Nat. Genet.* **21**, 326-329.

Bennett, C. N., Longo, K. A., Wright, W. S., Suva, L. J., Lane, T. F., Hankenson, K. D., and MacDougald, O. A. (2005). Regulation of osteoblastogenesis and bone mass by *Wnt10b*. *Proc. Natl. Acad. Sci. USA* **102**, 3324-3329.

Bi, W., Deng, J. M., Zhang, Z., Behringer, R. R. and de Crombrughe, B. (1999). *Sox9* is required for cartilage formation. *Nat. Genet.* **22**, 85-89.

Bialek, P., Kern, B., Yang, X., Schrock, M., Sobic, D., Hong, N., Wu, H., Yu, K., Ornitz, D. M., Olson, E. N., Justice, M. J., and Karsenty, G. (2004) A Twist code determines the onset of osteoblast differentiation. *Dev. Cell* **6**, 423-435.

Bodine, P. N., Zhao, W., Kharode, Y. P., Bex, F. J., et al. (2004). The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. *Mol. Endocrinol.* **18**, 1222-1237.

Bohmann, D., Bos, T. J., Admon, a., Nishimura, T., Vogt, P. K., and Tjian, R. (1987). Human proto-oncogene *c-jun* encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. *Science* **238**, 1386-1392.

Brown, J. R., Ye, H., Bronson, R. T., Dikkes, P., and Greenberg, M. E. (1996). A defect in nurturing in mice lacking the immediate early gene *fosB*. *Cell* **86**, 297-309.

Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998). Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. *Genes Dev.* **12**, 1260-1268.

Burgess, T. I., Quian, Y., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R. et al. (1999). The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. *J. Cell Biol.* **145**, 527-538.

Canalis, E. (1993). Insulin like growth factors and the local regulation of bone formation. *Bone* **14**, 173-276.

Capdevila, J., and Izpisua Belmonte, J. C. (2001). Patterning mechanisms controlling vertebrate limb development. *Annu. Rev. Cell Dev. Biol.* **17**, 87-132.

Carrasco, D., and Bravo, R. (1995). Tissue-specific expression of the fos-related transcription factor fra-2 during mouse development. *Oncogene* **10**, 1069-1079.

Chiu, R., Angel, P., and Karin, M. (1989). Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. *Cell* **22**, 979-986.

Chung, U. I., Schipani, E., McMahon, A. P., and Kronenberg, H. M. (2001). Indian hedgehog couples chondrogenesis osteogenesis in endochondral bone development. *J. Clin. Invest.* **107**, 295-304

Dacquin, R., Starbuck, M., Schinke, T., and Karsenty, G. (2002). Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. *Dev. Dyn.* **224**, 245-251.

David, J. P., Mehic, D., Bakiri, L., Schilling, A. F., Mandic, V., Priemel, M., Idarraga, M. H., Reschke, M. O., Hoffmann, O., Amling, M., and Wagner, E. F. (2005). Essential role of RSK2 in c-Fos-dependent osteosarcoma development. *J. Clin. Invest.* **115**, 664-672.

David, J. P., Sabapathy, K., Hoffmann, O., Idarraga M. H., and Wagner, E. F. (2002). JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. *J. Cell Sci.* **115**, 4317-4327.

Day, T. F., Guo, X., Garrett-Beal, L., and Yang, Y. (2005). Wnt/ β -Catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. *Dev. Cell* **8**, 739-750.

Deng, T., and Karin, M. (1993). JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. *Genes Dev.* **7**, 479-490.

Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., and Leder, P. (1996). Fibroblast growth factor receptor 3 is a negative regulator of bone growth. *Cell* **84**, 911-921

Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., and Karsenty, G. (1997). Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. *Cell* **89**, 747-754.

Eferl, R., Hoebertz, A., Schilling A. F., Rath, M., Karreth, F., Kenner, L., Amling, M., and Wagner, E. F. (2004). The Fos-related antigen Fra-1 is an activator of bone matrix formation. *Embo J.* **23**, 2789-2799.

Eferl, R., Sibilica, M., Hilberg, F., Fuchsbichler, A., Kufferath, I., Guertl, B., Zenz, R., Wagner, E. F. and Zatloukal, K. (1999). Functions of c-Jun in liver and heart development. *J. Cell Biol.* **145**, 1049-1061.

Eferl, R., and Wagner, E. F. (2003). AP-1: A double-edged sword in tumorigenesis. *Nat. Rev. Cancer* **3**, 859-868.

Felix, R., Cecchini, M. G., and Fleisch, H. (1990). Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. *Endocrinology* **127**, 2592-2594.

Fleischmann, A., Hafezi, F., Elliott, C., Reme, C. E., R  ther, U., and Wagner, E. F. (2000). Fra-1 replaces c-Fos-dependent functions in mice. *Genes Dev.* **14**, 2695-2700.

Fleischmann, A., Jochum, W., Eferl, R., Witowsky, J., and Wagner, E. F. (2003). Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene. *Cancer Cell* **4**, 477-482.

Franza, B. R., Rauscher, F. J., Josephs, S. F., and Curran, T. (1988). The Fos complex and Fos-related antigens recognize sequence elements that contain AP-1 binding sites. *Science* **239**, 1150-1153.

Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., Leonardi, A., Tran, T., Boyce, B. F., and Siebenlist, U. (1997). Requirement for NF-kappaB in osteoclast and B-cell development. *Genes Dev.* **11**, 3482-3496.

Gerald, D., Berra, E., Frapart, Y. M., Chan, D. A., et al. (2004). JunD reduces tumor angiogenesis by protecting cells from oxidative stress. *Cell* **118**, 781-794.

Gerber, H. P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, T., and Ferrara, N. (1999). VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. *Nat. Med.* **5**, 623-628.

Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D., et al. (2001). LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. *Cell* **107**, 513-523.

Grigoriadis, A. E., Schellander, K., Wang, Z. Q., and Wagner, E. F. (1993). Osteoblasts are target cells for transformation in c-fos transgenic mice. *J. Cell. Biol.* **122**, 685-701.

Grigoriadis, A. E., Wang, Z. Q., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., and Wagner, E. F. (1994). C-Fos: a key regulator of osteoclast-macrophage lineage determination and bone-remodelling. *Science* **266**, 443-448.

Gruda, M. C., van Amsterdam, J., Rizzo, C. A., Durham, S. K., Lira, S., and Bravo, R. (1996). Expression of FosB during mouse development: normal development of FosB knock out mice. *Oncogene* **12**, 2177-2185.

Haigh, J. J., Gerber, H. P., Ferrara, N., and Wagner, E. F. (2000). Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. *Development* **127**, 1445-1453

Hausler, K. D., Horwood, N. J., Chuman, Y., et al. (2004). Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. *J. Bone Miner. Res.* **19**, 1873-1881.

Hennigan, R. F., Hawker, K. L., and Ozanne, B. W. (1994). Fos-transformation activates genes associated with invasion. *Oncogene* **9**, 3591-3600.

Hess, J., Angel, P., and Schorpp-Kistner, M. (2004). AP-1 subunits: quarrel and harmony among siblings. *J. Cell. Sci.* **117**, 5965-5973.

Hess, J., Hartenstein, B., Teurich, S., Schmidt, D., Schorpp-Kistner, M., and Angel, P. (2003). Defective endochondral ossification in mice with strongly compromised expression of JunB. *J. Cell Sci.* **116**, 4587-4596.

Hilberg, F., Aguzzi, A., Howells, N., and Wagner, E. F. (1993). c-jun is essential for normal mouse development and hepatogenesis. *Nature* **365**, 179-181.

Hill, T. P., Später, D., Taketo, M. M., Birchmeier, W., and Hartmann, C. (2005). Canonical Wnt/ β -Catenin signalling prevents osteoblasts from differentiating into chondrocytes. *Dev. Cell* **8**, 727-738.

Hu, E., Mueller, E., Oliviero, S., Papaioannou, V. E., Johnson R., and Spiegelman, B. M. (1994). Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes. *Embo J.* **13**, 3094-3103.

Ikeda, F., Nishimura, R., Matsubara, T., Tanaka, S., Inoue, J., Reddy, S. V., Hata, K., Yamashita, K., Hiraga, T., Watanabe, T., et al. (2004). Critical roles of c-Jun signaling

in regulation of NFAT family and RANKL-regulated osteoclast differentiation. *J. Clin. Invest.* **114**, 475-484.

Imbra, R. J., and Karin, M. (1987). Metallothionein gene expression is regulated by serum factors and activators of protein kinase C. *Mol. Cell. Biol.* **7**, 1358-1363.

Inada, M., Yasui, T., Nomura, S., Miyake, S., Deguchi, K., Himeno, M., Sato, M., Yamagiwa, H., Kumura, T., and Yasui, N. (1999). Maturational disturbance of chondrocytes in Cbfa1-deficient mice. *Dev. Dyn.* **214**, 279-290

Ivanov, V. N., Bhoumik, A., Krasilnikov, M., Raz, R. et al. (2001). Cooperation between STAT3 and c-jun suppresses Fas transcription. *Mol. Cell.* **7**, 517-528.

Jilka, R. L., Hangoc, G., Giuseppe, G., Passeri, G., et al. (1992). Increased osteoclast development after estrogen loss: mediation by interleukin-6. *Science* **257**, 88-91.

Jochum, W., David, J. P., Elliot, C., Wutz, A., Plenk, H. J., Matsuo, K., and Wagner, E. F. (2000). Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. *Nat. Med.* **6**, 985-990.

Johnson, R., Spiegelman, B., Hanahan, D., and Wisdom, R. (1996). Cellular transformation and malignancy induced by ras requires c-jun. *Mol. Cell. Biol.* **16**, 4504-4511.

Johnson R. S., Spiegelman B. M., and Papaioannou, V. E. (1992). Pleiotropic effects of a null mutation in the c-fos proto-oncogene. *Cell* **71**, 577-586.

Johnson, R.S., van Lingen, B., and Papaioannou, V. (1992). A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture. *Genes Dev.* **7**, 1309-1317.

Jooss, K. U., and Muller, R. (1995). Deregulation of genes encoding microfilament-associated proteins during Fos-induced morphological transformation. *Oncogene* **10**, 603-608.

Kallunki, T., Su, B., Tsigelny, I., et al. (1994). JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. *Genes Dev.* **8**, 2996-3007

Kanzler, B., Kuschert, S. J., Liu, Y. H., and Mallo, M. (1998). Hoxa-2 restricts the chondrogenic domain and inhibits bone formation during development of the branchial area. *Development* **125**, 2587-2597.

Karaplis, A. C., Luz, A., Glowacki, J., Bronson, R. T., Tybulewicz, V. L., Kronenberg, H. M., and Mulligan, R. C. (1994). Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. *Genes Dev.* **8**, 277-289.

Karreth, F., Hoebertz, A., Scheuch, H., Eferl, R., and Wagner, E. F. (2004). The AP1 transcription factor Fra2 is required for efficient cartilage development. *Development* **131**, 5717-5725.

Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mahboudi, A., and Green, D. R. (1998). DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. *Mol. Cell* **1**, 3407-3416.

Kato, M., Patel, M. S., Levasseur, R., Lobov, I., Chang, B., Glass, D. A., Hartmann, C., Li, L., Huang, T.-H., Brayton, C. F., et al. (2001). Cbfa1/Runx2-independent decrease in osteoblast proliferation, osteopenia and persistent eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. *J Cell Biol.* **157**, 303-314.

Kenner, L., Hoebertz, A., Beil, T., Keon, N., Karreth, F., Eferl, R., Scheuch, H., Szremska, A., Amling, M., Schorpp-Kistner, M., Angel, P., and Wagner, E. F. (2004). Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. *J. Cell Biol.* **164**, 613-623.

Kim, S., Koga, T., Isobe, M., Kern, B., Yokochi, T. Chin, E. Y., Karsenty, G., Taniguchi, T., Takayanagi, H. (2003). Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation. *Genes Dev.* **17**, 1979-1991.

Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y. H., Inada, M., et al. (1997). Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell* **89**, 755-764.

Kong, Y. Y., Boyle, W. J., and Penninger, J. M. (1999). Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. *Immunol. Cell Biol.* **77**, 188-193.

Kveiborg, M., Sabatakos, G., Chiusaroli, R., Wu, M., Philbrick, W.M., Horne, W. C., and Baron, R. (2004). DeltaFosB induces osteosclerosis and decreases adipogenesis by two independent cell-autonomous mechanisms. *Mol. Cell. Biol.* **24**, 2820-2830.

Kwok, R. P., Lundblad, J. R. Chrivia, J. P., et al. (1994). Nuclear protein CBP is a coactivator for the transcription factor CREB. *Nature* **21**, 223-226.

Landschultz, W. H., Johnson, P. F., and McKnight, S. L. (1989). The DNA binding domain of the rat liver nuclear protein C/EBP is bipartite. *Science* **240**, 1759-1764.

Lanske, B., Karaplis, a. c., Lee, K., Luz, A., Vortkamp, A. Pirro, A., Karperien, M., Defize, L. H., Ho, C., Mulligan, R. C. et al. (1996). PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. *Science* **273**, 663-666

Lee, W., Haslinger, A., Karin, M., and Tijian, R. (1987). Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40. *Nature* **325**, 368-372.

Lee, W., Mitchell, P. J., and Tjian, R. (1987). Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. *Cell* **49**, 741- 752.

Li, B., Tournier, C., Davis, R. J., and Flavell, R. A. (1999). Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation. *Embo J.* **18**, 420-432.

Linsenmayer, T. F., Chen, Q., A., Gibney, E., Gordon, M. K., Marchant, J. K., Mayne, R., and Schmidt, T. M. (1991). Collagen types IX and X in the developing chick tibiotarsus: analyses of mRNAs and proteins. *Development* **111**, 191-196

Little, R. D., Carulli, J. P., Del Mastro, R. G., Depuis, J., Osborne, M., Folz, C., Maning, S. P., Swain, P. M., Zhao, S. C., Eustace, B., et al. (2002). A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. *Am. J. Hum. Genet.* **70**, 11-19.

Liu, Z., Xu, J., Colvin, J. S., and Ornitz, D. M. (2002). Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. *Genes Dev.*, **16**, 859-869

Lomaga, M. A., Yeh, W. C., Sarosi, I., Duncan, G. S., Furlonger, C., Ho, A., Morony, S., Capparelli, C., Van, G., and Kaufman, S. (1999). TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signalling. *Genes Dev.* **13**, 1015-1024.

Long, F., Schipani, E., Asahara, H., Kronenberg, H., and Montminy, M. (2001). The CREB family of activators is required for endochondral bone development. *Development* **128**, 541-550.

Lupu, F., Terwilliger, J. D., Lee, K., Segre, G.V., and Efstratiadis, A. (2001). Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. *Dev. Biol.* **229**, 141-162.

Ma, L., Golden, S., Wu, L., and Maxson, R. (1996). The molecular basis of Boston-type craniosynostosis: the Pro148→His mutation in the N-terminal arm of the MSX2 homeodomain stabilizes DNA binding without altering nucleotide sequence preferences. *Hum. Mol. Genet.* **5**, 1915-1920.

Marconcini, L., Marchio, S., Morbidelli, L., Cartocci, E., Albini, A., Ciche, M., Bussolino, F., and Oliviero, S. (1999). c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. *Proc. Natl. Acad. Sci. USA* **96**, 9671-9676.

Marusic, A., Katavic, V., Grcevic, D., and Lukic, I. K. (1999). Genetic variability of new bone induction in mice. *Bone* **25**, 25-32.

Matsuo, K., Owens, J. M., Tonko, M., Elliot, C., Chambers, T. J., Wagner, E. F. (2000). Fos1 is a transcriptional target of c-Fos during osteoclast differentiation. *Nat. Genet.* **24**, 184-187.

McHenry, J. Z., Leon, A., Matthei, K. I., and Cohen, D. R. (1998). Overexpression of fra-2 in transgenic mice perturbs normal eye development. *Oncogene* **17**, 1131-1140.

Meixner, A., Karreth, F., Kenner, L., and Wagner, E. F. (2004). JunD regulates lymphocyte proliferation and T helper cell cytokine expression. *Embo J.* **23**, 1325-1335.

Mizuno, D. R., Amizuka, N., Irie, K., et al. (1998). Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. *Biochem. Biophys. Res. Commun.* **247**, 610-615.

Mundlos, S., Otto, F., Mundlos, C., Mulliken, J. B., Aylsworth, A. S., Albright, S., Lindhout, D., Cole, W. G., Henn, W., Knoll, J. H., et al. (1997). Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. *Cell* **89**, 773-779.

Murakami, S., Kan, M., McKeehan, W. L., and de Crombrughe, B. (2000). Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by

the mitogen-activated protein kinase pathway. *Proc. Natl. Acad. Sci. USA.* **97**, 1113-1118

Nakashima, K., and de Crombrughe, B. (2003). Transcriptional mechanisms in osteoblast differentiation and bone formation. *Trends Genet.* **19**, 458-466

Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J. M., Behringer, R. R., and de Crombrughe, B. (2002). The novel zinc finger-containing transcription factor osteirix is required for osteoblast differentiation and bone formation. *Cell* **108**, 17-29.

Naski, M. C., Wang, Q., Xu, J., and Ornitz, D. M. (1996). Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. *Nat. Genet.* **13**, 233-237.

Nateri, A. S., Riera-Sans, L., Da Costa, C., and Behrens, A. (2004). The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. *Science* **303**, 1374-1378.

Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H. and Nakatani, Y. (1996). The transcriptional coactivators p300 and CBP are histone acetyltransferases. *Cell* **87**, 953-959.

Okada, S., Wang, Z. Q., Grigoriadis, A. E., Wagner, E. F. and von Rüden, T. (1994). Mice lacking c-fos have normal hematopoietic stem cells but exhibit altered B-cell differentiation due to an impaired bone marrow environment. *Mol. Cell. Biol.* **14**, 382-390.

Okazaki, K., and Sagata, N. (1995). The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells. *Embo J.* **14**, 5048-5059.

Ornitz, D.M., and Itoh, N. (2001). Fibroblast growth factors. *Genome Biol.* **2**, REVIEWS3005

Otto, F., Thornell, A. P., Crompton, T., et al. (1997). Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell* **89**, 765-771.

Park, J. M., Adam, R. M., Peters, C. A., Guthrie, P. D., Sun, Z., Klagsbrun, M., and Freeman, M. R. (1999). AP-1 mediates stretch-induced expression of HB-EGF in bladder smooth muscle cells. *Am. J. Physiol.* **277**, C294-C301.

Passegue, E., Jochum, W., Behrens, A., Ricci, R., and Wagner, E. F. (2002). JunB can substitute for Jun in mouse development and cell proliferation. *Nat. Genet.* **30**, 158-166.

Passegue, E., Jochum, W., Schorpp-Kistner, M., Möhle-Steinlein, U., and Wagner, E. F. (2001). Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. *Cell* **104**, 21-32.

Passegue, E., and Wagner, E. F. (2000). JunB suppresses cell proliferation by transcriptional activation of p16^{INK4A} expression. *EMBO J.* **19**, 2969-2979.

Raivich, G., Bohatschek, M., De Costa, C., Iwata, I., Galiano, M. et al. (2004). The AP-1 transcription factor c-Jun is required for efficient axonal regeneration. *Neuron* **43**, 57-67.

Rebollo, A., Dumoutier, L., Renauld, J. C., Zaballos, A., Ayllon, V., and Martinez-A, C. (2000). Bcl-3 expression promotes cell survival following interleukin-4 deprivation and is controlled by AP1 and AP1-like transcription factors. *Mol. Cell. Biol.* **20**, 3407-3416.

Reddi, A. H. (1997). Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. *Cytokine Growth factor Rev.* **8**, 11-20.

Reichmann, E., Schwarz, H., Deiner, E. M., Leiter, I., Eilers, M., Berger, J., Busslinger, M., and Beug, H. (1992). Activation of an inducible c-FosER fusion

protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversion. *Cell* **71**, 1103-1116.

Reimold, A. M., Grusby, M. J., Kosaras, B., Fries, J. M., Mori, R., Maniwa, s., Clauss, I. M., Collins, T., Sidman, R. L., Glimcher, M. J. et al. (1996). Chondrodysplasia and neurological abnormalities in ATF-2-deficient mice. *Nature* **379**, 262-265.

Ricci, R., Eriksson, U., Oudit, G. Y., Eferl, R., et al. (2005). Distinct functions of *junD* in cardiac hypertrophy and heart failure. *Genes Dev.* **19**, 208-213.

Sabatakos, G., Sims, N. A., Chen, J., Aoki, K., Kelz, M. B., Amling, M., Bouali, Y., Mukhopadhyay, K., Ford, K., Nestler, E. J., and Baron, R. (2000). Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. *Nat. Med.* **6**, 985-990.

Satokata, I., Ma, L., Ohshima, H., Bei, M., Woo, I., Nishizawa, K., Maeda, T. Takano, Y., Uchiyama, M., Heaney, S., et al. (2000). *Msx2* deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. *Nat. Genet.* **24**, 391-395.

Schipani, E., Kruse, K., and Juppner, H. (1995). A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. *Science* **268**, 98-100

Schipani, E., Lanske, B., Didrickson, S., Kobayashi, T., Knight, M., and Johnson, R. S. (2001). Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. *Genes Dev.* **15**, 2865-2876.

Schipani, E., Lanske, B., Hunzelman, J., Luz, A., Kovacs, C. S., Lee, K., Pirro, A., Kronenberg, H. M., and Juppner, H. (1997). Targeted expression of constitutively active receptors for parathyroid hormone and parathyroid hormone-related peptide delays endochondral bone formation and rescue mice that lack parathyroid hormone-related peptide. *Proc. Natl. Acad. Sci. USA* **94**, 13689-13694

Schorpp-Kistner, M., Wang, Z. Q., Angel, P., and Wagner, E. F. (1999). JunB is essential for mammalian placentation. *Embo J.* **18**, 934-948.

Schreiber, M., Kolbus, A., Piu, F., Szabowski, A., Möhle-Steinlein, U., Tian, J., Karin, M., Angel, P., and Wagner, E. F. (1999). Control of cell cycle progression by c-Jun is p53 dependent. *Cell* **13**, 607-619.

Schreiber, M., Wang, Z., Jochum, W., Fetka, I., Elliot, C., and Wagner, E. F. (2000). Placental vascularisation requires the AP-1 component fra1. *Development* **127**, 4937-4948.

Shaulian, E., Schreiber, M., Piu, F., Beeche, M., Wagner, E. F. and Karin, M. (2000). The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. *Cell* **103**, 897-907.

Simonet, S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H., Wooden, S., Bennett, T., and Boone, T. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* **89**, 309-319.

Smeal, T., Angel, P., Meek, J., and Karin, M. (1989). Different requirements for formation of Jun: Jun and Jun: Fos complexes. *Genes Dev.* **3**, 2091-2100

Stepniak, E., Ricci, R., Eferl, R., Sumara, G., Sumara, I., Rath, M., Hui, L., and Wagner, E. F. (2006). c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. *Genes Dev.* **20**, 2306-2314.

St-Jaques, B., Hammerschmidt, M., and McMahon, A. P. (1999). Indian hedgehog signalling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. *Genes Dev* **13**, 2072-2086

Sunters, A., Thomas, D. P., Yeudall, W. A. and Grigoriadis, A. E. (2004). Accelerated cell cycle progression in osteoblasts overexpressing the c-fos proto-oncogene: induction of cyclin A and enhanced CDK2 activity.

Takeda, S., Bonnamy, J. P., Owen, M. J., Ducky, P., and Karsenty, G. (2001). Continuous expression of Cbfa1 in non-hypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocytes differentiation and partially rescues Cbfa1-deficient mice. *Genes Dev.* **15**, 467-481.

Tallquist, M. D., and Soriano, P. (2000). Epiblast-restricted Cre expression in MORE mice: a tool to distinguish embryonic vs. extra-embryonic gene function. *Genesis* **26**, 113-115.

Thepot, D., Weitzman, J. B., Barra, J., Segretain, D., Stinnakre, M. G., Babinet, C., and Yaniv, M. (2000). Targeted disruption of the murine junD gene results in multiple defects in male reproductive function. *Development* **127**, 143-153.

Thomas, D. M., Johnson, S. A., Sims, N. A., Trivett, M. K., et al. (2004). Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. *J. Cell Biol.* **167**, 925-934.

Todaro, G. J., and Green, H. (1963). Quantitative studies of the growth of mouse embryo cells in culture and their development into established cell lines. *J. Cell. Biol.* **17**, 299-313.

Toft, D. J., Rosenberg, S. B., Bergers, G., Volpert, O., and Linzer, D. I. (2001). Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumour progression. *Proc. Natl. Acad. Sci. USA* **98**, 13055-13059.

Tondravi, M. M., McKercher, S. R., Anderson, K., Erdmann, J. M., Quiroz, M., Maki, R., and Teitelbaum, S. L. (1997). Osteopetrosis in mice lacking hematopoietic transcription factor PU.1. *Nature* **386**, 81-84.

Trachootham, D., Zhou, Y., Zhang, H., et al. (2006). Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. *Cancer Cell* **10**, 241-252.

Triboli, C., and Lufkin, T. (1999). The murine Bapx1 homeobox gene plays a critical role in embryonic development of the axial skeleton and spleen. *Development* **126**, 5699-5711.

Ueta, C., Iwamoto, M., Kantani, N., Yoshida, C., Liu, Y., Enomoto-Iwamoto, M., Ohmori, T., Enomoto, H., Nakata, K., Takada, K., et al. (2001). Skeletal malformations caused by overexpression of Cbfa1 or its dominant negative form in chondrocytes. *J. Cell Biol.* **153**, 87-100.

Vasseur, S., Hoffmeister, A., Garcia, S., Bagnis, C., Dagorn, C. J., and Iovanna, J. L. (2001). p8 is critical for tumour development induced by rasV12 mutated protein and E1A oncogene. *EMBO Rep.* **3**, 165-170.

Vu, T. H., Shipley, J. M., Bergers, G., Berger, J. E., Helms, J. A., Hanahan, D., Shapiro, S. D., Senior, R. M., and Werb, Z. (1998). MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. *Cell* **93**, 411-422.

Wagner, E. F., and Karsenty, G. (2001). Genetic control of skeletal development. *Curr. Opin. Genet. Dev.* **11**, 527-532

Wang, Z. Q., Grigoriadis, A. E., Möhle-Steinlein, U., and Wagner, E. F. (1991). A novel target cell for c-fos-induced oncogenesis: development of chondrogenic tumours in embryonic stem cell chimeras. *Embo J.* **10**, 2437-2450.

Wang, Z. Q., Liang, J., Schellander, K., Wagner, E. F., and Grigoriadis, A. F. (1995). c-fos- induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. *Cancer Res.* **55**, 6244-6251.

Wang, Z. Q., Ovitt, C., Grigoriadis, A. E., Möhle-Steinlein, U., Rüther, U., and Wagner, E. F. (1992). Bone and haematopoietic defects in mice lacking c-fos. *Nature* **360**, 741-745.

Weij, W., Jin, J., Schlisio, S., Harper, J. W., and Kaelin, W. G. Jr. (2005). The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. *Cancer Cell* **8**, 25-33.

Weitzman, J. B., Fiette, L., Matsuo, K., and Yaniv, M. (2000). JunD protects cells from p53-dependent senescence and apoptosis. *Mol. Cell* **6**, 1109-1119.

Whitfield, J., Neame, S. J., Paquet, L., Bernard, O., and Ham, J. (2001). Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. *Neuron* **29**, 629-643.

Wisdom, R., Johnson, R. S., and Moore, C. (1999). c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. *Embo J.* **18**, 188-197.

Yang, Y., Topol, L., Lee, H., and Wu, J. (2003). Wnt5a and Wnt5b exhibit distinct activities in coordinating chondrocyte proliferation and differentiation. *Development* **130**, 1003-1015.

Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S. I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., and Kuriyama, M. (1998). Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. *Endocrinology* **139**, 442-444.

Yoshida, Y., Tanaka, S., Umemori, H., Minowa, O., Usui, M., Ikematsu, N., Hosoda, E., Imamura, T., Kuno, J., Yamashita, T., et al. (2000). Negative regulation of BMP/Smad signalling by Tob in osteoblasts. *Cell* **103**, 1085-1097.

Yu, K., Xa, J., Liu, Z., Sasic, D., Shao, J., Olson, E. N., Towler, D. A., and Ornitz, D. M. (2003). Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signalling in the regulation of osteoblast function and bone growth. *Development* **130**, 3063-3074.

Zelzer, E., Glotzer, D. J., Hartmann, C., Thomas, D., Fukai, N., Soker, S., and Olsen, B.R. (2001). Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. *Mech. Dev.* **106**, 97-106.

Zenz, R., Scheuch, F., Martin, P., Frank, C., Eferl, R., Kenner, L., Sibilio, M., and Wagner, E. F. (2003). c-Jun regulates eyelid closure and skin tumour development through EGFR signaling. *Dev. Cell* **4**, 879-889.

Zhao, G., Monier-Faugée, M. C., Langub, M. C., Geng, Z., Nakayama, T., Pike, J. W., Chernauskis, S. D., Rosen, C. J., Donahue, L. R., Maluche, H., et al. (2000). Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. *Endocrinology* **141**, 2674-2682.